Generic Medicine Info
Indications and Dosage
Active progressive rheumatoid arthritis
Adult: Initially, 3 mg bid, or if tolerated, 6 mg once daily. If response is inadequate after 6 mth, increase dose to 3 mg tid. If response is still inadequate 3 mth later, discontinue treatment.
Should be taken with food. Take after meals or a light snack.
History of toxicity to gold compounds including necrotizing enterocolitis, pulmonary fibrosis, severe chronic dermatitis (e.g. exfoliative dermatitis, severe urticaria/eczema), severe haematological disorder (e.g. bone marrow aplasia, thrombocytopenia, leucopenia, aplastic anaemia). Concomitant use w/ clozapine, antimalarial agents, penicillamine, and immunosuppressive agents. Lactation.
Special Precautions
Patient w/ inflammatory bowel disease, history of bone marrow depression, acute porphyria, DM, HTN, CHF. Patient undergoing radiotherapy. Hepatic (e.g. hepatocellular disease) and renal impairment (e.g. progressive renal failure). Pregnancy.
Adverse Reactions
Nausea w/ or w/o vomiting, abdominal pain, loose stools/diarrhoea, anorexia, flatulence, dyspepsia, dysgeusia, constipation; rash, pruritus, hair loss, urticaria, photosensitivity; stomatitis, conjunctivitis, glossitis; anaemia, leucopenia, granulocytopenia, thrombocytopenia, eosinophilia; haematuria, proteinuria, increased BUN and serum creatinine; elevated liver enzymes.
Monitoring Parameters
Monitor CBC w/ differential, platelet count, and urinalysis at baseline and during therapy. Monitor hepatic and renal function.
Symptoms: Dizziness, headache, flushing, tachyarrhythmia, palpitation, thrombocytopenia, kidney and liver effects. Management: Supportive treatment. Induce emesis or employ gastric lavage.
Drug Interactions
Altered absorption and increased toxicity w/ drugs affecting GI motility (e.g. prokinetics, loperamide, senna). May cause blood dyscrasias w/ phenylbutazone, oxyphenbutazone, levamisole, high-dose corticosteroids. May increase risk of vasomotor reaction w/ ACE inhibitors. May cause renal impairment or proteinuria w/ aminoglycosides, amphotericin B, penicillins, phenytoin, sulfonamides, NSAIDs, aciclovir. May increase plasma concentration of phenytoin.
Potentially Fatal: May cause an additive risk of haematological toxicity and renal AR w/ clozapine, antimalarial agents (e.g. chloroquine, hydroxychloroquine, atovaquone/proguanil, mefloquine, quinine), penicillamine. May cause serious hepatotoxicity and haematological toxicity w/ immunosuppressive agents (e.g. leflunomide).
Lab Interference
May enhance response to tuberculin skin test.
Description: Auranofin is a synthetic gold compound that exhibits anti-inflammatory, antiarthritic, and immunomodulating effects. It is taken up by macrophages, resulting in inhibition of phagocytosis and lysosomal membrane stabilisation. Additionally, it inhibits prostaglandin synthesis and decreases serum rheumatoid factor, complement activation, and lysosomal enzyme release.
Absorption: Incompletely (approx 25%) absorbed from the GI tract.
Distribution: Penetrates into synovial fluid; approx 40% is associated w/ RBCs. Plasma protein binding: 60%.
Metabolism: Rapidly metabolised.
Excretion: Mainly via faeces (84-92%); urine (9-17%, approx 60% as absorbed gold. Elimination half-life: 21-31 days.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. CID=24199313, (accessed on Jan. 21, 2020)

Store between 15-30°C. Protect from light.
MIMS Class
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
ATC Classification
M01CB03 - auranofin ; Belongs to the class of gold preparations of antirheumatic agents.
Anon. Auranofin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 17/10/2016.

Buckingham R (ed). Auranofin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 17/10/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Auranofin. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 17/10/2016.

Ridaura Capsule (Prometheus Laboratories Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 17/10/2016.

Disclaimer: This information is independently developed by MIMS based on Auranofin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in